Access & reimbursement

Eli Lilly’s retatrutide could reset obesity care, but rising demand and grey-market access are testing regulators and health systems

Can AstraZeneca challenge the obesity market leaders? New GLP-1 data signal growing ambitions beyond oncology

GIST Care Looks Beyond First-Generation KIT Control

Pancreatic Cancer Finally Gets a RAS Moment

A Rare Pain Disorder Gets a Pivotal Trial

EMA backs first oral obesity GLP-1 as pills push treatment towards mass-market adoption

As GLP-1 use expands, healthcare systems are confronting a new challenge: balancing obesity treatment with rising concerns about eating disorders and patient safety.

GSK’s Nuvalent Deal Turns Lung Cancer Precision Into a $10.6 Billion Access Race

J&J’s Firefly Bio Deal Puts KRAS Back Into the Oncology Arms Race
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
